BriaCell Therapeutics Corp. (BCTXZ) Stock Price & Analysis
BriaCell Therapeutics Corp. (BCTXZ) closed at USD 0.16 on Thursday, October 15, 2026, down 7.94% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.17; the Oct 15, 2026 session ranged USD 0.16–0.18 on volume of 11,210 shares. Market capitalization is —, with a 52-week range of USD 0.16–0.18 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BCTXZ.md
Key facts (BCTXZ)
- Analysts: None.
Analysts (BCTXZ)
Consensus None.
Key Statistics (as of October 16, 2026 at 05:11 UTC)
| Price | USD 0.16 |
|---|---|
| Change | ▼ 7.94% (down) |
| Previous Close | USD 0.17 |
| Open | USD 0.18 |
| Day Range | USD 0.16 – 0.18 |
| 52-Week Range | USD 0.16 – 0.18 |
| Volume | 11,210 shares |
| Market Cap | — |
| Exchange | NCM |
Analyst Ratings (BCTXZ)
Wall Street analysts rate BCTXZ "None", per Nexqual as of October 16, 2026 at 05:11 UTC.
| Consensus Rating | None |
|---|
Earnings (BCTXZ)
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Financials & Fundamentals (BCTXZ)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -175.25% |
| Current Ratio | 7.07 |
| Total Cash | $22.80M |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Financial Health Score (BCTXZ)
Nexqual rates BriaCell Therapeutics Corp.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:11 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $23M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$31M (TTM) |
| Efficiency | Critical — ROE -175%, ROA -90.8% |
Ownership (BCTXZ)
| Float | 7.86M |
|---|
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Leadership (BCTXZ)
BriaCell Therapeutics Corp. is led by William V. Williams FCPA (age 70), CEO, President & Director, per Nexqual as of October 16, 2026 at 05:11 UTC.
| CEO, President & Director | William V. Williams FCPA (age 70) |
|---|---|
| CFO & Corporate Secretary | Gadi Levin B.Com., C.A. (age 52) |
| Chief Scientific Officer | Miguel A. Lopez-Lago (age 55) |
Major Backers & Investors (BCTXZ)
Notable institutional backers of BriaCell Therapeutics Corp. include Heights Capital Management, Inc , Sabby Management, LLC, Susquehanna International Group, LLP, according to Nexqual as of October 16, 2026 at 05:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Heights Capital Management, Inc | 13.44% |
| Sabby Management, LLC | 5.18% |
| Susquehanna International Group, LLP | 4.91% |
| HRT Financial LP | 2.91% |
| Two Sigma Securities, LLC | 0.65% |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BCTXL | BriaCell Therapeutics Corp. Warrant expiring 2031 | USD 0.89 | ▼ 1.36% |
| BFRIW | Biofrontera Inc. Warrants | USD 0.01 | ▼ 7.14% |
| ASBPW | Aspire-Lakewood Holdings, Inc. | USD 0.01 | ▲ 0% |
| APLMW | Apollomics Inc. Warrant | USD 0.01 | ▲ 1.98% |
| BEATW | Heartbeam, Inc. Warrant | USD 0.01 | ▼ 5.32% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt